drugset / Trial / NCT05360732

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

NCT05360732 ↗

Phase 2 Active not recruiting 37 enrolled Fox Chase Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This is a multi- centered two-stage Pilot Study assessing the tolerability and toxicity of an alternating regimen of FOLFOX and FOLFIRI for the treatment of newly diagnosed and untreated metastatic pancreatic cancer in patients over the age of 65 years.

Timeline

Start
2022-04-22
Primary completion
2026-09-01
Completion
2026-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 180 mg/m2 Intravenous
Subject Leucovorin Small molecule 400 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous